Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice

Experimental Neurology

Volumn 126, Issue 2, 1994, Pages 195-204

  Muthane, U ^a   Ramsay, K A ^a   Jiang, H ^a   Jackson Lewis, V ^a   Donaldson, D ^a   Fernando, S ^a   Ferreira, M ^a   Przedborski, S ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CALBINDIN; DOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; MALE; MOUSE; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

3,4-DIHYDROXYPHENYLACETIC ACID; ANALYSIS OF VARIANCE; ANIMAL; BIOLOGICAL MARKERS; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; COMPARATIVE STUDY; CORPUS STRIATUM; HOMOVANILLIC ACID; HUMAN; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MPTP POISONING; NEURONS; PARKINSON DISEASE; REFERENCE VALUES; SPECIES SPECIFICITY; SUBSTANTIA NIGRA; SUPPORT, NON-U.S. GOV'T; TYROSINE 3-MONOOXYGENASE;

EID: 0028302235     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1006/exnr.1994.1058     Document Type: Article

References (49)

1. Abercrombie, M. 1946. Estimation of nuclear population from microtome sections. Anat. Ree. 94: 239-247.
2. Agid, Y., F. Javoy-Agid, and M. Ruberg. 1987. Biochemistry of neurotransmitters in Parkinson’s disease. Movement Disorders 2 (C. D. Marsden and S. Fahn, Eds.), pp. 166-230. Butterworths, London.
3. Baker, H., T. H. Joh, and D. J. Reis. 1980. Genetic control of number of midbrain dopaminergic neurons in inbred strains of mice: Relationship to size and neuronal density of the striatum. Proc. Natl. Acad. Sci. USA 77: 4369-4373.
4. Beal, M. F., B. T. Hyman, and W. Koroshetz. 1993. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 16: 125-131.
5. Burke, R. E., and A. L. Karanas. 1990. Quantitative morphological analysis of striatal cholinergic neurons in perinatal asphyxia. Ann. Neurol. 27: 81-88.
6. Burke, R. E., A. Macaya, D. Devivo, N. Kenyon, and E. M. Janec. 1992. Neonatal hypoxic-ischemic or excitotoxic striatal injury results in a decreased adult number of substantia nigra neurons. Neuroscience 50: 559-569.
7. Burns, R. S., C. C. Chiueh, S. P. Markey, M. H. Ebert, D. M. Jacobowitz, and I. J. Kopin. 1983. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of substantia nigra by N-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80: 4546-4550.
8. Burns, R. S., P. A. Lewitt, M. H. Ebert, H. Pakkenberg, and I. J. Kopin. 1984. The clinical syndrome of striatal dopamine deficiency: Parkinsonism induced by l-methyI-4-phenyl-l, 2, 3, 6-tetrahydropyridine (MPTP). N. Engl. J. Med. 312: 1418-1421.
9. Chan, P., L. E. Delanney, I. Irwin, J. W. Langston, and D. Di Monte. 1991. Rapid ATP loss caused by l-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in mouse brain. J. Neurochem. 57: 348-351.
10. Clarke, P. G. H. 1985. Neuronal death in the development of the vertebrate nervous system. Trends Neurosci. 8: 345-349.
11. Cleeter, M. W., J. M. Cooper, and A. H. Schapira. 1992. Irreversible inhibition of mitochondrial complex I by l-methyl-4-phenylpyridinium: evidence for free radical involvement. J. Neurochem. 58: 786-789.
12. Davis, G. C., A. C. Williams, S. P. Markey, M. H. Ebert, E. D. Caine, C. M. Reichert, and I. J. Kopin. 1979. Chronic parkinsonism secondary to intravenous injection of meperidine analogs. Psych. Res. 1: 249-254.
13. Di Monte, D., S. A. Jewell, G. Ekstrom, M. S. Sandy, and M. T. Smith. 1986. l-Methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine (MPTP) and l-methyl-4-phenylpyridinium (MPP+) cause rapid ATP depletion in isolated hepatocytes. Biochem. Biophys. Res. Commun. 137: 310-315.
14. Eldridge, R., and S. E. Ince. 1984. The low concordance rate for Parkinson’s disease in twins: a possible explanation. Neurology 34:1354-1356.
15. Ellis, R. E., J. Yuan, and H. R. Horvitz. 1991. Mechanisms and functions of cell death, Annu. Rev. Cell Biol. 7: 663-698.
16. Forno, L. S., L. E. Delanney, I. Irwin, and J. W. Langston. 1993. Similarities and differences between MPTP-induced parkinsonism and Parkinson’s disease: Neuropathologie considerations. Adv. Neurol. 60: 600-608.
17. Gaspar, P., C. W. Heizmann, and J. H. Kaas. 1993. Calbindin D-28K in the dopaminergic mesocortical projection of a monkey (Aoius trivirgatus) Brain Res. 603:166-172.
18. Gerfen, C. R., K. G. Baimbridge, and J. J. Miller. 1985. The neostriatal mosaic: Comparmental distribution of calciumbinding protein and parvalbumin in the basal ganglia of the rat and monkey. Proc. Natl. Acad. Sci. USA 82: 8780-8784.
19. German, D. C., K. F. Manaye, P. K. Sonsalla, and B. A. Brooks. 1992. Midbrain dopaminergic cell loss in Parkinson’s disease and MPTP-induced parkinsonism: Sparing of calbindin-D28k-contain-ingcells. Ann. N.Y.Acad. Sci. 648: 42-62.
20. Giovanni, A., B. A. Sieber, R. E. Heikkila, and P. K. Sonsalla. 1991. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following l-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine administration to several strains of mice. J. Pharmacol. Exp. Ther. 257: 691-697.
21. Hasegawa, E., K. Takeshige, T. Oishi, Y. Murai, and S. Minakami. 1990. l-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-depen-dent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun. 170:1049-1055.
22. Heikkila, R. E. 1985. Differential neurotoxicity of l-methyl-4-phenyl-tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources. Eur. J. Pharmacol. 117:1451-1453.
23. Heikkila, R. E., A. Hess, and R. C. Duvoisin. 1984. Dopaminergic neurotoxicity of l-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyri-dine in mice. Science 224: 1451-1453.
24. Heikkila, R. E., L. Manzino, F. S. Cabbat, and R. C. Duvoisin. 1984, Protection against the dopaminergic neurotoxicity of l-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467-469.
25. Heikkila, R. E., B. A. Sieber, L. Manzino, and P. K. Sonsalla. 1989. Some features of the nigrostriatal dopaminergic neurotoxin l-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine (MPTP) in the mouse. Mol. Chem. Neuropatkol. 10: 171-183.
26. Irwin, L, L. E. Delanney, D. Di Monte, and J. W. Langston. 1989. The biodisposition of MPP+ in mouse brain. Neurosci. Lett. 101:83-88.
27. Janec, E., and R. E. Burke. 1993. Naturally occurring cell death during postnatal development of the substantia nigra pars compacta of rat. Mol. Cell. Neurosci. 4: 30-35.
28. Javitch, J. A., R. J. D’Amato, S. M. Strittmatter, and S. H. Snyder. 1985. Parkinsonism-inducing neuro toxin, N-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine: uptake of the metabolite N-methyI-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA 82: 2173-2177.
29. Kass, G. E. N., J. M. Wright, P. Nicotera, and S. Orrenius. 1988. The mechanism of l-methyl-4-phenyl-l, 2, 3, 6-tetrahy-dropyridine toxicity: Role of intracellular calcium. Arch. Bio-chem. Biophys. 260: 789-797.
30. Kopin, I. J. 1987. MPTP: An industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson’s disease. Environ. Health Perspect. 75: 45-51.
31. Kopin, I. J., and S. P. Market. 1988. MPTP toxicity: Implication for research in Parkinson’s disease. Annu. Rev. Neurosci. 11: 81-96.
32. Langston, J. W., P. Ballard, and I. Irwin. 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980.
33. Langston, J. W., and I. Irwin. 1986. MPTP: Current concepts and controversies. Clin. Neuropharmacol. 9: 485-507.
34. Markey, S. P., J. N. Johannessen, C. C. Chiueh, R. S. Burns, and M. A. Herkenham. 1984. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311: 464-467.
35. Naini, A. B., S. Przedborski, V. Jackson Lewis, H. Jiang, and L. Cote, 1992. MPTP administration causes catacholamine depletion in the brain of the chick embryo. Mov. Disord. 7(Suppl. 1): 58.
36. Nicklas, W. J., S. K. Yougster, M. V. Kindt, and R. E. Heikkila. 1987. MPTP, MPP+ and mitochondrial function. Life Sci. 40: 721-729.
37. Oppenheim, R. W., D. Prevette, M. Tytell, and S. Homma. 1990. Naturally occurring and induced neuronal death in the chick embryo in vivo requires protein and RNA synthesis: evidence for the role of cell death genes. Dev. Biol. 138:104-113.
38. Parisi, J. E., and R. S. Burns. 1985. MPTP-induced parkinsonism in man and experimental animals. J. Neuropathol. Exp. Neurol. 44: 325.
39. Przedborski, S., V. Kostic, V. Jackson-Lewis, J. L. Cadet, and R. E. Burke. 1991. Effect of unilateral perinatal hypoxic-ischemic brain injury in the rat on dopamine D1 and D2 receptors and uptake sites: a quantitative autoradiographic study. J. Neurochem. 57:1951-1961.
40. Przedborski, S-, V. Kostic, V. Jackson-Lewis, A. B. Naini, S. Simonetti, S. Fahn, E. Carlson, C. J. Epstein, and J. L. Cadet. 1992. Transgenic mice with increased Cu/Zn-superoxide dismu-tase activity are resistant to N-methyl-4-phenyl-1, 2, 3, 6-tetrahy-dropyridine-induced neurotoxicity. J. Neurosci. 12: 1658-1667.
41. Ramsey, R. R., and T. Singer. 1986. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of l-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine, by mitochondria. J. Biol Chem. 261: 7585-7587.
42. Reches, A., H. R. Wagner, D. Jiang, V. Jackson, and S. Fahn. 1982. The effect of chronic L-DOPA administration on supersensitive pre-and postsynaptic dopaminergic receptors in rat brain. Life Sci. 31: 37-44.
43. Schneider, J. S., A. Yuwiler, and C. H. Markham. 1986. Production of a Parkinson-like syndrome in the cat with N-methyI-4-phenyl-l, 2, 3, 6,-tetrahydropyridine (MPTP): Behavior, histology, and biochemistry. Exp. Neurol. 91: 293-307.
44. Schotcher, K. P., I. Irwin, L. E. Delanney, J. W. Langston, and D. Dì Monte, 1990. Effects of l-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine and l-methyl-4-phenylpyridinium ion on ATP levels of mouse brain synaptosomes. J. Neurochem. 54: 1295-1301.
45. Schwartz, L. M., L. Kosz, and B. K. Kay. 1990. Gene activation is required for developmentally programmed cell death. Proc. Natl. Acad. Sci. USA 87: 6594-6598.
46. Sidman, R. L., J. B. Angevine, Jr., and E. T. Pierce. 1971. Atlas of the Mouse Brain and Spinal Cord, Harvard University Press, Cambridge.
47. Sonsalla, P. K., and R. E. Heikkila. 1986. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur. J. Pharmacol. 129: 339-345.
48. Vyas, I., R. E. Heikkila, and W. J. Nicklas. 1986. Studies on the neurotoxicity of l-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine: Inhibition of NAD-Iinked substrate oxidation by its metabolite, l-methyI-4-phenylpyridinium. J. Neurochem. 46: 1501-1507.
49. Williams, R. W., and K. Herrup. 1988. The control of neuron number. Annu. Rev. Neurosci. 11: 423-453.